Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6695583 | 0.91 | APEX1 (0.46) | MAPTGAASMN1; SMN2ADORA1LMNA | |
| SCHEMBL6693258 | 0.88 | GAA (0.55) | MAPTGAASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL7031115 | 0.87 | MAPT (0.50) | MAPTGAASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL6695993 | 0.86 | MAPT (0.49) | MAPTGAASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL6698125 | 0.86 | MAPT (0.49) | MAPTGAASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL6700078 | 0.86 | KMT2A (0.53) | MAPTGAAL3MBTL1KMT2AADORA2A | |
| SCHEMBL6695754 | 0.84 | MAPT (0.69) | MAPTGAASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL11709649 | 0.84 | MAPT (0.69) | MAPTGAASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL6713986 | 0.81 | MAPT (0.45) | MAPTGAASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL6690817 | 0.81 | MAPT (0.55) | MAPTGAASMN1; SMN2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224965-A1 | 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors | MERCK PATENT GMBH (DE) | 2004-11-11 | — | — | US | claimed |
| EP-1274691-A1 | 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS | MERCK PATENT GmbH (DE) | 2003-01-15 | — | — | EP | claimed |
| WO-2001079186-A1 | 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS | MERCK PATENT GMBH (DE) | 2001-10-25 | — | — | WO | claimed |
| US-20040224965-A1 | 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors | MERCK PATENT GMBH (DE) | 2004-11-11 | — | — | US | disclosed |
| EP-1274691-A1 | 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS | MERCK PATENT GmbH (DE) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001079186-A1 | 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS | MERCK PATENT GMBH (DE) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224965-A1 | 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors | NHERF1, SLC9A3, SLC9A1 | MAPT 4292/4885GAA 666/4885SMN1; SMN2 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.